Ewings Sarcoma Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, Japan - Size and Forecast 2024-2028

Published: Oct 2023

Pages: 158

SKU: IRTNTR72933

Snapshot

Ewing's Sarcoma Treatment Market 2024-2028

The global Ewing's sarcoma treatment market size is estimated to grow by USD 205.09 million at a CAGR of 6.26% between 2023 and 2028.

Key Findings:

Ewing's sarcoma treatment market remained historically at high levels from 2018 to 2023.
The market is segmented into End-user, Type, and Geography.
The Hospitals sub segment under the end-user category generated the largest revenue in 2018.
Key regions boosting the market growth include North America, Europe, Asia, and Rest of World (ROW).

Ewing's Sarcoma Treatment Market Share

For More Highlights About this Report, Download Free Sample in a Minute

Ewing's Sarcoma Treatment Market: Key Drivers, Trends and Challenges

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Ewing's Sarcoma Treatment Market Driver

One of the key factors driving the market growth is the regulatory incentives for Ewings sarcoma treatment. This disease is a rare bone tumor that occurs in childhood. For instance, as per the NH, approximately 3 per 1 million children each year are diagnosed with an. Ewing's sarcoma. In addition, Ewing's sarcoma accounts for about 1.5 percent of all childhood cancers, and it is the second-most common type of bone tumor in children.

Moreover, As Ewing's sarcoma is a rare disease, to date, no cure has been developed for it, as rare diseases lack sponsors owing to the expensive research and the prospect of limited profit. Therefore, to overcome this challenge, regulatory authorities in several countries are granting special drug designations, such as orphan drug designation, which qualifies a drug for special financial incentives, including tax credits for qualified clinical trials. Hence, such factors drive the market growth during the forecast period.

Key Ewing's Sarcoma Treatment Market Trends

A key factor shaping the Ewings sarcoma treatment market growth is the emergence of regenerative therapies. There have been significant advancements in terms of the treatment of metastatic Ewing's sarcoma and recurrent Ewing's tumors in the global Ewings sarcoma treatment market. In addition, one of the most advanced and extensively researched treatment methods is regenerative medicine, including gene therapy.

Moreover, in gene therapy, the mutated gene is withdrawn from the patient and is genetically modified in a laboratory and administered to the patient. The genetically modified gene replaces the mutated genes. In addition, there are several pharmaceutical companies developing and studying gene therapy to treat metastatic Ewing's sarcoma and recurrent Ewing's tumors in patients. Hence, such factors are positively impacting the market. Therefore, it is expected to drive the market growth during the forecast period.

Major Ewing's Sarcoma Treatment Market Challenge

The lack of approved therapies for Ewings sarcoma is a challenge that affects market growth. Ewing's sarcoma is a life-threatening sarcoma arising in the bone and soft tissue of adolescents and young adults. The primary tumor is treated with surgery or radiation, depending on the possibility of resection. Owing to the high rate of spreading, even in patients with localized disease, patients are also treated with chemotherapeutics, such as vincristine, doxorubicin, and cyclophosphamide, to eradicate microscopic tumors that could lead to distant metastases and death.

Furthermore, numerous clinical trials evaluating new chemotherapeutic agents against recurrent Ewing's sarcoma are underway. However, the therapies are in early-stage clinical trials and are not expected to be launched in the next five years, which may impede the growth of the global Ewings sarcoma treatment market during the forecast period.

Ewing's Sarcoma Treatment Market Segmentation

The end-user segment includes hospitals, specialty clinics, and others. The type segment includes combination therapy and monotherapy. The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW).

End-User Segment

The market share growth by the hospitals segment will be significant during the forecast period. This segment is the key end-users that influence market growth. In addition, manufacturers of Ewing's sarcoma treatment therapeutics focus on delivering high-quality products to hospitals to improve brand image and thereby expand their product reach. Furthermore, large hospitals, such as multispecialty hospitals, work under government sponsorship or through private entities.

Get a glance at the market contribution of various segments Download the PDF Sample

The hospitals segment was valued at USD 259.28 million in 2018. Moreover, these hospitals have more than 500 hospital beds, allowing the accommodation of individuals from within the locality and neighboring areas. In addition, they procure medical products and consumables in bulk and engage closely with many suppliers, reimbursement authorities, and government organizations. Furthermore, they also have an advanced medical infrastructure to cater to the needs of the people. Therefore, the need for Ewing's sarcoma treatment therapeutics in hospitals will increase due to the growing number of hospital admissions for surgical care. Hence, such factors are fueling the growth of this segment which in turn drives the market growth during the forecast period.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 48% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America dominates the global Ewing's sarcoma treatment market due to high prevalence and treatment accessibility. In the region's developed countries, the annual incidence of Ewing's sarcoma is significant, with 3 children per 1 million population, and 200-250 cases in the US each year. Increasing awareness and funding, supported by organizations like the Sarcoma Foundation of America, contribute to research and education. Rising research funding has led to novel therapies' development, focusing on targeted treatments and combination therapies. Industry and clinical research collaborations, such as those with Aadi Bioscience Inc., are driving growth. Limited approved therapies and upcoming late-stage drug launches further accelerate market momentum in North America.

Key Companies in Ewing's Sarcoma Treatment Market

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Advantech Co. Ltd.: The company offers Ewings sarcoma treatment drugs such as INBRX-109 which is a tetravalent, agonistic antibody targeting death receptor 5 (DR5), a proapoptotic receptor for the trimeric tumor necrosis factor related apoptosis inducing ligand.

The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Ewing's Sarcoma Treatment Market Scope
Report Coverage	Details
Page number	158
Base year	2023
Historic period	2018 - 2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 6.26%
Market growth 2024-2028	USD 205.09 million
Market structure	Fragmented
YoY growth 2023-2024(%)	5.74
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 48%
Key countries	US, Canada, UK, Germany, and Japan
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Actiza Pharmaceutical Pvt. Ltd., Advantech Co. Ltd., Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Fresenius Kabi AG, GlaxoSmithKline Plc, Gradalis Inc., Johnson and Johnson, LGM Pharma LLC, Merck and Co. Inc., Novartis AG, Ocean pharmaceutical, Pfizer Inc., PharmaMar SA, Salvavidas, and UPMC Hillman Cancer Center
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download PDF Sample

What are the Key Data Covered in this Ewing's Sarcoma Treatment Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the market between 2024 and 2028
Precise estimation of the size of the market size and its contribution of the market in focus to the parent market
Accurate predictions about upcoming trends and changes in consumer behaviour
Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
Thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements.

Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global Ewings sarcoma treatment market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global ewings sarcoma treatment market 2018 - 2022 ($ million)

4.2 End-user Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – End-user Segment 2018 - 2022 ($ million)

4.3 Type Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Type Segment 2018 - 2022 ($ million)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by End-user

6.1 Market segments
- Exhibit 30: Chart on End-user - Market share 2023-2028 (%)
- Exhibit 31: Data Table on End-user - Market share 2023-2028 (%)

6.2 Comparison by End-user
- Exhibit 32: Chart on Comparison by End-user
- Exhibit 33: Data Table on Comparison by End-user

6.3 Hospitals - Market size and forecast 2023-2028
- Exhibit 34: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)

6.4 Specialty clinics - Market size and forecast 2023-2028
- Exhibit 38: Chart on Specialty clinics - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Specialty clinics - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Specialty clinics - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Specialty clinics - Year-over-year growth 2023-2028 (%)

6.5 Others - Market size and forecast 2023-2028
- Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)

6.6 Market opportunity by End-user
- Exhibit 46: Market opportunity by End-user ($ million)
- Exhibit 47: Data Table on Market opportunity by End-user ($ million)

7 Market Segmentation by Type

7.1 Market segments
- Exhibit 48: Chart on Type - Market share 2023-2028 (%)
- Exhibit 49: Data Table on Type - Market share 2023-2028 (%)

7.2 Comparison by Type
- Exhibit 50: Chart on Comparison by Type
- Exhibit 51: Data Table on Comparison by Type

7.3 Combination therapy - Market size and forecast 2023-2028
- Exhibit 52: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 53: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 54: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)

7.4 Monotherapy - Market size and forecast 2023-2028
- Exhibit 56: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)

7.5 Market opportunity by Type
- Exhibit 60: Market opportunity by Type ($ million)
- Exhibit 61: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 Canada - Market size and forecast 2023-2028
- Exhibit 87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on Canada - Year-over-year growth 2023-2028 (%)

9.9 UK - Market size and forecast 2023-2028
- Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.10 Germany - Market size and forecast 2023-2028
- Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.11 Japan - Market size and forecast 2023-2028
- Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ million)
- Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption

11.4 Industry risks
- Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 109: Vendors covered

12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification

12.3 Advantech Co. Ltd.
- Exhibit 111: Advantech Co. Ltd. - Overview
- Exhibit 112: Advantech Co. Ltd. - Business segments
- Exhibit 113: Advantech Co. Ltd. - Key offerings
- Exhibit 114: Advantech Co. Ltd. - Segment focus

12.4 Amneal Pharmaceuticals Inc.
- Exhibit 115: Amneal Pharmaceuticals Inc. - Overview
- Exhibit 116: Amneal Pharmaceuticals Inc. - Business segments
- Exhibit 117: Amneal Pharmaceuticals Inc. - Key news
- Exhibit 118: Amneal Pharmaceuticals Inc. - Key offerings
- Exhibit 119: Amneal Pharmaceuticals Inc. - Segment focus

12.5 Baxter International Inc.
- Exhibit 120: Baxter International Inc. - Overview
- Exhibit 121: Baxter International Inc. - Business segments
- Exhibit 122: Baxter International Inc. - Key news
- Exhibit 123: Baxter International Inc. - Key offerings
- Exhibit 124: Baxter International Inc. - Segment focus

12.6 Bristol Myers Squibb Co.
- Exhibit 125: Bristol Myers Squibb Co. - Overview
- Exhibit 126: Bristol Myers Squibb Co. - Product / Service
- Exhibit 127: Bristol Myers Squibb Co. - Key news
- Exhibit 128: Bristol Myers Squibb Co. - Key offerings

12.7 Cellectar Biosciences Inc.
- Exhibit 129: Cellectar Biosciences Inc. - Overview
- Exhibit 130: Cellectar Biosciences Inc. - Product / Service
- Exhibit 131: Cellectar Biosciences Inc. - Key offerings

12.8 Daiichi Sankyo Co. Ltd.
- Exhibit 132: Daiichi Sankyo Co. Ltd. - Overview
- Exhibit 133: Daiichi Sankyo Co. Ltd. - Product / Service
- Exhibit 134: Daiichi Sankyo Co. Ltd. - Key news
- Exhibit 135: Daiichi Sankyo Co. Ltd. - Key offerings

12.9 Eli Lilly and Co.
- Exhibit 136: Eli Lilly and Co. - Overview
- Exhibit 137: Eli Lilly and Co. - Product / Service
- Exhibit 138: Eli Lilly and Co. - Key news
- Exhibit 139: Eli Lilly and Co. - Key offerings

12.10 Fresenius Kabi AG
- Exhibit 140: Fresenius Kabi AG - Overview
- Exhibit 141: Fresenius Kabi AG - Business segments
- Exhibit 142: Fresenius Kabi AG - Key news
- Exhibit 143: Fresenius Kabi AG - Key offerings
- Exhibit 144: Fresenius Kabi AG - Segment focus

12.11 GlaxoSmithKline Plc
- Exhibit 145: GlaxoSmithKline Plc - Overview
- Exhibit 146: GlaxoSmithKline Plc - Business segments
- Exhibit 147: GlaxoSmithKline Plc - Key news
- Exhibit 148: GlaxoSmithKline Plc - Key offerings
- Exhibit 149: GlaxoSmithKline Plc - Segment focus

12.12 Gradalis Inc.
- Exhibit 150: Gradalis Inc. - Overview
- Exhibit 151: Gradalis Inc. - Product / Service
- Exhibit 152: Gradalis Inc. - Key offerings

12.13 Johnson and Johnson
- Exhibit 153: Johnson and Johnson - Overview
- Exhibit 154: Johnson and Johnson - Business segments
- Exhibit 155: Johnson and Johnson - Key news
- Exhibit 156: Johnson and Johnson - Key offerings
- Exhibit 157: Johnson and Johnson - Segment focus

12.14 Novartis AG
- Exhibit 158: Novartis AG - Overview
- Exhibit 159: Novartis AG - Business segments
- Exhibit 160: Novartis AG - Key offerings
- Exhibit 161: Novartis AG - Segment focus

12.15 Ocean pharmaceutical
- Exhibit 162: Ocean pharmaceutical - Overview
- Exhibit 163: Ocean pharmaceutical - Product / Service
- Exhibit 164: Ocean pharmaceutical - Key offerings

12.16 Pfizer Inc.
- Exhibit 165: Pfizer Inc. - Overview
- Exhibit 166: Pfizer Inc. - Product / Service
- Exhibit 167: Pfizer Inc. - Key news
- Exhibit 168: Pfizer Inc. - Key offerings

12.17 PharmaMar SA
- Exhibit 169: PharmaMar SA - Overview
- Exhibit 170: PharmaMar SA - Business segments
- Exhibit 171: PharmaMar SA - Key offerings
- Exhibit 172: PharmaMar SA - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 173: Inclusions checklist
- Exhibit 174: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 175: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 176: Research methodology
- Exhibit 177: Validation techniques employed for market sizing
- Exhibit 178: Information sources

13.5 List of abbreviations
- Exhibit 179: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

ewing's sarcoma treatment market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis